ProQR Therapeutics N.V. (PRQR)
1.64
0.01 (0.61%)
At close: Mar 21, 2025, 3:59 PM
0.61% (1D)
| Bid | 1.59 |
| Market Cap | 172.02M |
| Revenue (ttm) | 24.43M |
| Net Income (ttm) | -35.83M |
| EPS (ttm) | -0.35 |
| PE Ratio (ttm) | -4.67 |
| Forward PE | -3.7 |
| Analyst | Buy |
| Ask | 1.9 |
| Volume | 585,559 |
| Avg. Volume (20D) | 403,788 |
| Open | 1.63 |
| Previous Close | 1.63 |
| Day's Range | 1.59 - 1.65 |
| 52-Week Range | 1.59 - 4.62 |
| Beta | 0.24 |
About PRQR
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in...
Industry Biotechnology
Sector Healthcare
IPO Date Sep 18, 2014
Employees 166
Stock Exchange NASDAQ
Ticker Symbol PRQR
Website https://www.proqr.com
Analyst Forecast
According to 6 analyst ratings, the average rating for PRQR stock is "Buy." The 12-month stock price forecast is $9.5, which is an increase of 481.04% from the latest price.
Stock ForecastsEarnings Surprise
ProQR Therapeutics has released their quartely earnings
on Mar 13, 2025:
4 months ago
+5.6%
ProQR Therapeutics shares are trading higher afer ...
Unlock content with
Pro Subscription
7 months ago
+12.57%
Pro QR Therapeutics shares are trading higher after the company reported better-than-expected Q1 EPS results.
